Ascentage Pharma Group International

NASDAQ:AAPG

Biotechnology

Healthcare
$12.44 +1.78%

+$0.31 today

Market cap
$1.16B
Beta
0.65
P/E (TTM)
-8.9
EPS (TTM)
-$13.29
52W Low $16.92High $48.45

Volume 0.00M

Average 0.01M

Returns on capital

Ascentage Pharma Group International management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-91.2%

avg -144.0%

ROIC

-33.3%

avg -33.0%

ROA

-30.5%

avg -36.9%

Analysis

ROA is currently the strongest return metric at -30.5% versus its period average of -36.9%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Dajun Yang

Co-Founder, Chairman & Chief Executive OfficerCNY 6.16M630<0.01%

Shaomeng Wang

Co-Founder, Chief Scientific Advisor & Non-Executive DirectorCNY 241.08K6117.96K0.08%

James Ziegler

Chief Commercial Officer—60——

Chongdong Fu

Senior Vice President & Head of CMC————

Veet Misra

Chief Financial Officer——18.58K0.08%

Yifan Zhai

Chief Medical Officer—630<0.01%

Jin Cao

Head of Finance—405.40K0.02%

Thomas Joseph Knapp

Senior Vice President & General Counsel—73——

Yuly Chen

Senior Director of Investor Relations————

Ming Guo

Co-Founder—68——

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding May 21, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

No open-market purchases or sales in the last 12 months.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A2 analysts
RevenueN/AN/A+38.6%
+68.6% (5yr)6 analysts
Net IncomeN/AN/AN/A
N/A6 analysts
EBITN/AN/AN/A
N/A6 analysts

Analysis

Recent growth has been strongest in Revenue at +38.6% over three years. Forward estimates point to Revenue at +68.6% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does Ascentage Pharma Group International compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about AAPG's management, answered from reported figures.

Who manages AAPG?

Ascentage Pharma Group International (AAPG) lists 10 active executives. The top listed executive is James Ziegler, Chief Commercial Officer.

Are AAPG insiders buying or selling?

Recent insider activity shows net buying of $8.43M.